In the field of vaccines and drugs related to the new crown, the Food and Drug Administration approved Pfizer's new crown virus treatment drug to be listed with conditions; Eli Lilly's new crown neutralizing antibody Bebtelovimab obtained the FDA's emergency use authorization and reached a purchase order of 720 million US dollars; due to the rapid changes in the epidemic situation, AstraZeneca announced to abandon the new crown vaccine for the beta variant...
In terms of policy, the Health and Health Commission has made major adjustments: the CDC and the Comprehensive Supervision Bureau have been revoked, the Medical Administration and Hospital Administration has been renamed the Medical Administration Department, and the Health Emergency Office has been renamed the Medical Emergency Department; the State Information Office has held a regular policy briefing, emphasizing " Centralized procurement does not pursue the lowest price, and also firmly opposes running bidding"-
In terms of personnel changes, Ben Yong, chief medical officer of BeiGene Immuno-Oncology, resigned, and Mark C. Lanasa, the former global clinical head of late-stage development of AstraZeneca Oncology, took over.